Lilly and EVA Pharma launch locally made Insulin in Egypt
December 2024- The Egyptian Drug Authority approved the insulin glargine injection manufactured…
‘‘We Want To Become The Most Digital And AI-driven Company In Our Industry’’ – Thierry Bernard
Taking the time to have a productive discussion with experts yields insightful…
Lilly expands manufacturing footprint in Ireland
September 2024- Eli Lilly and Company announced a $1 billion expansion of…
Could single-Dose Zepbound Vials be a game-changer for weight loss?
August 2024- Eli Lilly and Company announced Zepbound ® (tirzepatide) 2.5 mg…
Tirzepatide Cuts Type 2 Diabetes Risk by 94% in Adults with Pre-Diabetes and Obesity
INDIANAPOLIS- Eli Lilly and Company announced today positive topline results from the SURMOUNT-1…
Lilly and OpenAI Team Up Against Superbugs
June 2024- Eli Lilly and Company announced a collaboration with OpenAI that…
Lilly, UNICEF expand support to help millions of young people at risk of NCDs
Geneva- During the World Health Assembly, Eli Lilly and Company announced it…
DOH-Abu Dhabi and Eli Lilly Suisse S.A Partners on Neurodegenerative Disease patient care
May 2024- The Department of Health – Abu Dhabi (DoH) and Eli…
Nearly one-half of patients on mirikizumab achieved endoscopic response at 52 weeks
May 2024- In Eli Lilly and Company's pivotal Phase 3 VIVID-1 study,…
FDA Approves Eli Lilly’s Zepbound™ for Obesity Treatment
INDIANAPOLIS: Eli Lilly and Company's (NYSE: LLY) innovative obesity treatment, Zepbound™ (tirzepatide)…
